Craig-Hallum analyst John Wilkin initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $15 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies Holds Annual Shareholders Meeting
- Adaptive Biotechnologies highlights new data at ASCO Meeting, EHA Congress
- Adaptive Biotechnologies price target raised to $13 from $11 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Adaptive Biotechnologies price target raised to $9 from $7 at Morgan Stanley